On February 28, 2019, Shanghai Longyao Biotechnology Co., Ltd. and Jiangsu Provincial People's Hospital held a CAR-T clinical research cooperation project meeting. The personnel of the two parties jointly discussed matters related to the initiation of clinical research of CAR-T in the Pharmacy Building of Jiangsu Provincial People's Hospital. The meeting was presided over by the Science and Technology Department of Jiangsu Provincial People's Hospital, and relevant personnel from the Hospital Science and Technology Department, Ethics Committee, Clinical Research, Hematology Department and Longyao Biology attended the meeting.
meeting venue
First, Chairman Ye Shengqin introduced the achievements of our company in the research and development and transformation of CAR-T and other immune cell technologies in recent years. Chairman Ye Shengqin pointed out that Shanghai Longyao Bio is a national high-tech enterprise in Shanghai, and has the advantages of the whole industry chain in the research and development and transformation of immune cell technology, technology platform, technology application, etc.; especially in the research and development of new CAR-T products. Strong technical originality; Jiangsu Provincial People's Hospital is a tertiary first-class general hospital with strong comprehensive strength in Jiangsu Province. The Department of Hematology is a national key clinical specialty and a key clinical specialty of the Jiangsu Provincial Health and Health Commission, and has important influence. Director Li Jianyong of the Department of Hematology is the chairman of the Hematology and Tumor Professional Committee of the China Anti-Cancer Association and an authoritative expert in the field of hematology and tumor; the cooperation between the two parties will be launched soon. The clinical studies of the two CAR-T products are technologically advanced.
Ye Shengqin, Chairman of Longyao Biology, delivered a speech
Li Jianyong, director of the Department of Hematology of Jiangsu Provincial People's Hospital, introduced the general situation, main advantages and global influence of the Department of Hematology. Director Li said, but the Department of Hematology of Jiangsu Provincial People's Hospital has done a lot of exploration in establishing the clinical system of CAR-T in the early stage, and the experience is relatively mature. It is hoped that after the cooperation, the two parties will supervise each other, standardize the operation, and have the confidence to make the cooperation project better.
Li Jianyong, Director of the Department of Hematology, Jiangsu Provincial People's Hospital
Fan Lei, deputy director of the Department of Hematology of Jiangsu Provincial People's Hospital, also mentioned that Shanghai Longyao Bio is not the first CAR-T company that Jiangsu Provincial People's Hospital cooperated with, and has already gained good experience in the field of tumor cell therapy. And firmly believe that under the strict management of the hospital and the close cooperation between the company and the hospital, we can grow together and jointly accelerate the promotion of the project.
Fan Lei, Deputy Director of the Department of Hematology, Jiangsu Provincial People's Hospital
In this meeting, Professor Yang Xuanming of Shanghai Jiaotong University, the chief scientist of Shanghai Longyao Biology, introduced the scientific research progress of our company's CAR-T. The cooperation between the two parties is based on two layouts of CAR-T products: first, adding new costimulatory factors to traditional CAR-T has shown better tumoricidal effect in mice and human trials; second, cord blood The source of general-purpose CAR-T is comparable to traditional CAR-T in tumoricidal effect, supplemented by TCR knockout technology to ensure the safety of general-purpose CAR-T, and finally realize the industrial application of general-purpose CAR-T. Director Li and Director Fan gave many valuable suggestions and future research directions on the scientific research results of CAR-T based on their rich clinical experience.
Professor Yang Xuanming, Chief Scientist of Longyao Biology
In the end, the two sides had an in-depth discussion on the content of the clinical program of the clinical trial, such as the inclusion criteria, exclusion criteria, and dose escalation of the clinical trial. At the same time, the materials and procedures to be submitted by the Jiangsu Provincial People's Hospital Ethics Committee were also determined. Both parties hope to further establish cooperation in exploratory clinical research in other fields of cell therapy based on the establishment of the CAR-T clinical research standard system and jointly apply for industrial park projects.
meeting venue